We Would Recommend Owning Prosensa At Current Levels, Says Roth Capital
In a research note released today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Prosensa Holding (NASDAQ:RNA) with a $17 price target, which represents a potential upside of 89% from where the stock is currently trading.
Chattopadhyay noted, “Drisapersen’s pivotal is likely to mimic eteplirsen in duration and primary endpoint, in our view. However, Prosensa may elect not to perform invasive biopsies for Dystrophin analysis. Drisapersen’s study, although a few months behind eteplirsen, could enroll faster since Prosensa has blocking IP in the EU, which restricts Sarepta to North America. With multiple clinical and regulatory milestones during 2015, we would recommend owning Prosensa at current levels.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -0.5% and a 35.9% success rate. Chattopadhyay has a -5.7% average return when recommending RNA, and is ranked #2501 out of 3315 analysts.